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Background: The autologous hematopoietic stem cell transplantation procedure involves
immunosuppression of the patient. Thus, the patient has an elevated risk for several dis-
eases, such as infections with the varicella-zoster virus. Prevention protocols have been
proposed based on the use of acyclovir from the ﬁrst day of conditioning, and maintaining
this drug for 30–100 days after the procedure or for as much as one year. The objective of
this work was to evaluate the incidence of herpes zoster after autologous transplantations
related to the early suspension of acyclovir.
Methods: A retrospective study was carried out based on the collection of data from 231
medical records of transplant patients in the Bone Marrow Transplant Unit of the teaching
hospital of the Universidade Federal de Juiz de Fora in the period between 2004 and 2014.
Results: Fourteen (6.1%) patients had herpes zoster in the post-transplant period on average
within six months of the procedure. Patients with multiple myeloma (64.3%) were the most
affected. There was a statistically signiﬁcant difference in the age of the patients, with older
individuals having a greater chance of developing the infection (p-value = 0.002). There were
no  signiﬁcant differences for the other variables analyzed.
Conclusion: The early suspension of acyclovir can be safe in patients who receive autolo-
gous hematopoietic stem cell transplants. However some groups may beneﬁt from extended
prophylaxis with acyclovir, particularly older patients and patients with multiple myeloma.©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
common of which are antibiotic, antiviral and antifungalIntroduction
Autologous hematopoietic stem cell transplants (HSCT) are
usually recommended as a recovery therapy for patients who
receive myeloablative chemotherapy.1 The immunosuppres-
sion caused by the conditioning leaves the patient at a high
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risk of acquiring different types of diseases. Infections are
an important cause of morbidity in this process.2 These
patients therefore receive prophylactic medications, the mostSão Pedro, 36037-754 Juiz de Fora, MG, Brazil.
agents.
Viruses, usually of the herpes family, such as the herpes
simplex virus (HSV), cytomegalovirus (CMV) or varicella-zoster
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Of the 14 patients who had HZ in the post-HSCT period,
only one was taking corticosteroids/thalidomide during the
onset of the infection (7.21%). Furthermore, only one patient
Table 1 – Characteristics of the population.
Variable n Percentage (%)
Gender
Male 135 58.7
Female 95 41.3
Diagnosis
Multiple myeloma 120 52.2
Lymphomas 97 42.2
Other diseases 13 5.7
Diabetes
Presence 17 7.4
Absence 213 92.6rev bras hematol hemot
irus (VZV), are some of the most common causes of infections
n the period after HSCT.3
Herpes zoster (HZ) is a painful vesicular eruption that
s typically restricted to one or two dermatomes. It is the
esult of the reactivation of latent VZV virus in nervous
anglia, usually many  years after the primary infection.4 Infec-
ions caused by the varicella-zoster virus are quite common
fter HSCT, occurring in approximately 20–30% of patients
ubmitted to autologous transplants within one year after
ransplantation.4–6 Studies have shown that the occurrence
f HZ is more  common after the third month after transplant,
ith an incidence peak in the fourth month.5
The use of acyclovir as prophylaxis against the reactivation
f herpes is considered standard care during neutropenia in
utologous HSCT patients.7 Different protocols include the
rophylactic use of acyclovir on the ﬁrst day of chemother-
py (conditioning), maintaining its use until Day 30–100 after
SCT in the absence of immunosuppression.8
In the Bone Marrow Transplant Unit of the Universi-
ade Federal de Juiz de Fora (UFJF), the start of prophylaxis
ith acyclovir occurs on the ﬁrst day of chemotherapy, and
s suspended when the neutrophil count is greater than
00 cells/mm3, i.e. when engraftment occurs, resulting in less
ime of use than recommended. The present study therefore
ims to evaluate the incidence of infection by the herpes virus
n patients submitted to autologous HSCT in respect to the
arly suspension of acyclovir.
ethods
his retrospective study compared the incidence of HZ in
atients submitted to autologous HSCT with early interrup-
ion of prophylactic acyclovir compared to the usual scheme
f one year reported in the literature.
The medical records of 221 patients submitted to HSCT in
he period between 2004 and 2014 at the Bone Marrow Trans-
lantation Unit of the UFJF, were analyzed retrospectively. Of
hese, nine patients underwent two transplants, totaling 230
rocedures.
ata  collection  and  variables
he data were collected from medical records. Data collection
ccurred in the period from March to September 2014. For the
haracterization of the population, data was collected related
o gender, age, diagnosis, presence or absence of diabetes, in
ddition to the occurrence of death. Additionally, the occur-
ence of herpes before and after HSCT and other variables of
nterest were studied including the time of use of acyclovir,
uration of neutropenia, length of hospitalization, use of cor-
icosteroids or thalidomide after an outbreak of herpes, and
he time of onset of the disease after the transplant. Although
ome records presented prior serology for HZ, many  patients
ere not tested and thus the analysis of this variable was not
erformed.All patients submitted to autologous BMT, independent of
he baseline disease, received prophylactic acyclovir at a dose
f 500 mg/m2/day divided in 2–4 doses per day according to
he period in which the procedure was performed. Prophylaxis 1 6;3  8(4):298–301 299
was starting on the ﬁrst day of conditioning and suspended
when the neutrophil count was greater than 500 cells/mm3.
After hospital discharge, the patients were monitored on
an outpatient basis for a period of 24 months in the transplant
service of the UFJF.
Data collection was only started after approval by
the Research Ethics Committee of the UFJF (# CAAE
25735614.3.0000.5133).
Statistical  analysis
The data were analyzed using the Statistical Package for the
Social Sciences software (version 19.0 for Windows). The Chi-
square test was used for categorical variables and Student’s
t-test for numerical variables, means and medians. A p-value
<0.05 was considered statistically signiﬁcant.
Results
Two hundred and thirty medical records were analyzed. The
mean age was 48.73 years (range: 4–79) and most patients
were male (58.7%). The most commonly found diagnosis in
the transplant service was multiple myeloma, totaling 52.2% of
hospital admissions. The average length of hospital stay of the
patients was 20.78 days. The characteristics of the population
are described in Table 1.
Few patients had some type of associated comorbidity, with
diabetes mellitus being the most common, occurring in 7.4%
(n = 17) of the patients.
Eight patients (3.5%) had had HZ before hospitalization to
perform the HSCT, only one of whom (0.43%) also presented HZ
after the HSCT. Fourteen (6.1%) patients presented HZ after the
HSCT; there were no signiﬁcant differences in the evaluated
variables between patients who had HZ after the HSCT and
those that did not (Table 2). The average time of onset of the
HZ outbreak was 164.6 days after the transplant (median: 144;
range: 49–330 days).Death
Yes 67 29.1
No 163 70.9
300  rev bras hematol hemoter. 2 0 1 6;3  8(4):298–301
Table 2 – Occurrence of herpes after the autologous hematopoietic stem cell transplant and characteristics of the
population.
Characteristics Occurrence of herpes after HSCT p-Value
Yes % No %
Gender
Female 3 21.1 92 42.6 0.119
Male 11 78.6 124 57.4
Diagnosis
Multiple myeloma 9 64.3 111 51.4 0.477
Lymphomas 5 35.7 92 42.6
Other diseases 0 0 13 6.0
Diabetes
Yes 2 14.3 15 6.9 0.275
No 12 85.7 201 93.1
Death
Yes 2 14.3 65 30.1 0.289
No 12 85.7
Total 14 100 
Table 3 – Occurrence of herpes after the autologous
hematopoietic stem cell transplant regarding age,
duration of acyclovir treatment and neutropenia.
Characteristics Mean p-Value
Age
Herpes yes 57.14 0.001
Herpes no 48.19
Prophylactic use of acyclovir in days
Herpes yes 18.57 0.690
Herpes no 19.13
Duration of neutropenia in days
Herpes yes 8.82 0.350
Herpes no 9.15
(7.21%) had a relapse of the disease. Moreover, one patient
incurred the infection during mobilization, prior to HSCT.
Most patients who  developed HZ were patients with multi-
ple myeloma (64.3%). Table 3 lists some characteristics related
to the incidence of HZ.
A statistically signiﬁcant difference was observed regarding
the age of the patients who had herpes and those who did not
develop it, with older patients having a higher likelihood of
developing HZ. Considering only the patients with lymphoma
or myeloma together with HZ, the difference in age was not
signiﬁcant; the ﬁrst group had a mean age of 52.40 years and
the second, 59.78 years (p-value = 0.233).
Discussion
The prophylactic use of acyclovir in the Bone Marrow trans-
plant Unit of the UFJF starts on the ﬁrst day of chemotherapy
and ends when engraftment occurs. Fourteen patients (6.1%)
had outbreaks of HZ after HSCT. Different protocols provide
for the prophylactic use of acyclovir from the ﬁrst day of
chemotherapy (conditioning) to Day 30 or Day 100 after HSCT
in the absence of immunosuppression, and possibly as long
as one year of prophylaxis.7,8151 69.9
217 100
However, there is insufﬁcient evidence to strongly support
the prolonged use of acyclovir in autologous HSCT, or to sug-
gest that its effectiveness outweighs the potential adverse
consequences.5,9 Studies have reported that the continuous
use of 400 mg/day of acyclovir until the end of immunosup-
pressive therapy may not suppress the reactivation of VZV
after the discontinuation of acyclovir.6 The prophylactic bene-
ﬁts should therefore be weighed against the toxicity, cost and
risk of inducing resistance. In the analysis of allogeneic trans-
plantations, however, the use of acyclovir for up to one year
proved to be effective in the prevention of the reactivation of
VZV.6,8,10 In transplants performed using umbilical cord stem
cells, an increased incidence of VZV was also demonstrated
(46%) thereby justifying extended prophylaxis.11
Data from the literature demonstrated the probability of
reactivation of VZV in 8.2% of the patients who  received low
prophylactic doses of acyclovir for one year.12 In patients
who did not receive acyclovir or who took it for a shorter
period (until the end of neutropenia), the rates increased to
21–25%.3,12 In the current study, 14 patients had outbreaks
of HZ after HSCT, with an incidence of 6.1%, that is, a lower
value than that found in the literature. This factor indicates
that early suspension of acyclovir may be considered in sta-
ble patients. However, the present study has the limitation of
being retrospective.
One study showed that the underlying disease might be a
risk factor for the development of HZ. In a study conducted
by Schuchter et al.,3 the infection occurred mainly in patients
with Hodgkin’s or non-Hodgkin lymphoma (46%), compared
with leukemia (20%) and solid tumors (9%), differing from this
study, in which the greatest number of cases, albeit insignif-
icant, occurred with patients with multiple myeloma (64.3%),
followed by lymphoma (35.7%).
With respect to the age of the patients who incurred
HZ, this study showed a statistical difference; HZ primar-
ily affected patients with a more  advanced age. This data is
also demonstrated in another study, in which an age greater
than 50 years was considered a risk factor for infection with
VZV.13
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The use of thalidomide has a potential immunosuppress-
ve effect. One case study reported a disseminated infection
aused by herpes simplex and an infection with VZV ﬁve years
fter autologous HSCT in a patient taking thalidomide.14 In
his study, however, only one of the patients who had HZ took
his medication.
Although no serology is performed before the transplant,
 prior history of HZ has a strong relationship with the posi-
ivity of the serologic testing.15 In this speciﬁc case, only one
f the eight patients who had had HZ prior to the transplant
uffered a recurrence of the disease. This leads us to believe
hat performing serology for HZ before the HSCT may not be
ecessary, as this would indicate the extended use of acyclovir
n patients with positive results.
New measures, such as vaccination against HZ, are being
mplemented. Previous studies have shown that the results
f this measure may be negligible, since the vaccine is not
ecommended within the ﬁrst year after transplant (live atten-
ated vaccine) and the incidence of VZV is rare after this
eriod.15 More  recent studies, however, using immunization
wo months after HSCT with an adjuvant subunit of varicella-
oster virus glycoprotein E, have shown it to be a reasonable
trategy to reduce HZ in autologous HSCT patients.4
Even though it was not in the scope of this article to assess
he survival rate of patients, the mortality rate, regardless of its
ause, was not inﬂuenced by the occurrence of HZ infection.
Although this work evaluated the records of 230 trans-
lants, it was necessary to compare the data found with
tudies carried out in other institutions because this was a
ingle center study. We  conclude that the early suspension of
cyclovir can be safe in low-risk patients submitted to autolo-
ous HSCT. This makes it possible to reduce not only the risk
f resistance to medication, but the treatment costs. However,
ome groups may beneﬁt from extended prophylaxis with acy-
lovir, particularly older patients and patients with multiple
yeloma.
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